• Aug 15, 2017
    Medical Device Company Relocates U.S. Headquarters to Atlanta, GA
    Dune Medical Devices taps into the Southeast medtech ecosystem to expand its radiofrequency (RF) Spectroscopy device portfolio Dune Medical Devices, makers of MarginProbe, announced today the company will relocate their U.S. headquarters to Alpharetta (Atlanta), Georgia. According to Dune Medical CEO Lori Chmura the move from Paoli, Pennsylvania to Atlanta will help accomplish key strategic initiatives including clinical uptake and reimbursement for MarginProbe as well as the expansion of the company’s cancer detection device portfolio.“Atlanta’s high concentration of hospitals, engineers...
  • Aug 10, 2017
    Dune Medical Company Update
    The successes that Dune Medical has celebrated, and the milestones attained in 2016, have set a strong foundation that has helped propel us into 2017. We continue to build on the early successes that we have had in 2017, as we leverage our recent funding round, new web presence and add fresh perspectives to our management team: always striving to better patient outcomes and answer the question – “Did we get it all?” – for breast cancer surgeons and...
  • Jul 27, 2017
    Leading Breast Surgeon Reviews Current Treatment Environment and How to Address High Reexcision Rates
    Dr. Molly Sebastian had very personal reasons for becoming a breast surgeon. “My mom went through breast cancer treatment while I was in physical training and this was a big contributor to why I choose this specialty,” she shared. “My mother’s surgeon ended up becoming my partner for 8 years and that relationship shaped a lot of what I do today in my approach to care for patients. I feel like it’s a real privilege to help people out...
  • Jul 18, 2017
    The Atlanta Business Chronicle: Medical device company raises $12.3 million, plans move to Atlanta
    Dune Medical’s CEO Lori Chmura on the company’s $12.3M investment, plans to relocate, and making RF Spectroscopy the standard of care in cancer treatment to ensure that surgeons “get it all.”"It’s really a challenge that's out there, and it's a huge cost to the health-care system as well as a pretty big stress to the patient," said Lori Chmura, CEO of Dune Medical Devices. "It's really important to get all the cancer out the...
  • Jul 13, 2017
    Dune Medical raises $12M to take RF Spectroscopy technology beyond breast cancer
    The future of RF spectroscopy and Dune’s recent investment round featured by MassDevice and FierceBiotechDune Medical’s recent $12.3M investment round led by Canepa Healthcare, ATON Partners, and the Kraft Group was recently highlighted by both MassDevice and FierceBiotech. The funding opens doors for our company to develop new solutions which are developed on a first-of-its-kind RF Spectroscopy platform that differentiates cancerous from healthy tissue based on electromagnetic properties, making it possible for patients and physicians to answer the question,...
- Enter Your Location -
- or -